CD8A and neoplasm: To assess the impact of XL413 plus Olaparib treatment on the tumor microenvironment, we analyzed the tumor‐infiltrating immune cells and found that the combination treatment significantly increased the percentage of tumor‐infiltrating CD8+ T cells, but not that of CD4+ T cells or B cells (Figure S6G, Supporting Information).